5 Key Takeaways

• 1

  BioAge Labs has initiated the QUELL-DME trial, dosing the first participant with the investigational oral NLRP3 inhibitor, BGE-102.

• 2

  The Phase 2 trial will enroll approximately 180 participants and evaluate BGE-102 as monotherapy and in combination with anti-VEGF therapy.

• 3

  The primary endpoint of the study is the change in best-corrected visual acuity at week 12, with topline results expected in late 2027.

• 4

  Participants will be randomized into three treatment groups, receiving either anti-VEGF plus placebo, anti-VEGF plus BGE-102, or sham injection plus BGE-102.

• 5

  BGE-102 is a novel small-molecule inhibitor targeting the NLRP3 inflammasome, implicated in inflammatory processes associated with diabetic macular edema.